Ubs Group Ag Humanigen, Inc Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.13 - $0.2 $41,769 - $64,260	-321,302 Reduced 99.56%	1,430 $0
Q1 2023 May 12, 2023	BUY	$0.12 - $0.23 $13,989 - $26,813	116,581 Added 56.55%	322,732 $45,000
Q4 2022 Feb 08, 2023	BUY	$0.09 - $0.2 $13,832 - $30,739	153,695 Added 293.0%	206,151 $24,000
Q3 2022 Nov 10, 2022	BUY	$0.15 - $3.02 $7,697 - $154,968	51,314 Added 4493.35%	52,456 $10,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $24,007 - $52,658	-13,264 Reduced 92.07%	1,142 $3,000
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $1.59 Million - $3.58 Million	-435,317 Reduced 96.8%	14,406 $53,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $2.58 Million - $7.76 Million	435,197 Added 2995.99%	449,723 $2.67 Million
Q2 2021 Aug 13, 2021	SELL	$13.54 - $22.74 $1 Million - $1.69 Million	-74,152 Reduced 83.62%	14,526 $253,000
Q1 2021 May 12, 2021	BUY	$12.91 - $23.83 $1.14 Million - $2.11 Million	88,678 New	88,678 $1.69 Million
Q4 2020 Feb 11, 2021	SELL	$7.97 - $21.66 $14,266 - $38,771	-1,790 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$8.0 - $28.5 $14,320 - $51,015	1,790 New	1,790 $19,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.